Physician profile
Daniel A Patterson
NPI 1285644708
$35,594.42
in general payments reported to CMS, 2019-2025
74 companies · $3,353 in 2025
The $3,353 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,298 · 2021: $3,094 · 2022: $3,202 · 2023: $2,547 · 2024: $4,521 · 2025: $3,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,885 · Long Term Medical Supply Or Device Loan: $1,446 · Education: $90.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,884.65 |
| Long Term Medical Supply Or Device Loan | $1,446.39 |
| Education | $90.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $11,524.77 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $5,082.90 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $3,700.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,616.62 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Lilly USA, LLC | $874.62 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $829.62 | 2019-2025 | |
| Astellas Pharma US INC | $734.60 | 2020-2025 | Xospata, Xtandi, Padcev |
| Eisai INC. | $725.41 | 2019-2025 | |
| Emd Serono, INC. | $683.52 | 2019-2025 | Bavencio |
| Amgen INC. | $634.47 | 2019-2024 | Prolia, Evenity, Blincyto |
| Jazz Pharmaceuticals INC. | $584.92 | 2021-2025 | |
| Seagen INC. | $467.01 | 2019-2023 | Tukysa, Adcetris |
| Foundation Medicine, INC. | $446.49 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $440.37 | 2019-2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $382.64 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $364.17 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $337.73 | 2020-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $320.24 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $319.35 | 2019-2025 | |
| Janssen Biotech, INC. | $261.29 | 2020-2023 | Imbruvica |
| Sobi, INC | $220.94 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $216.94 | 2020-2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $213.67 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.44 | 2019-2025 | Iclusig, Alunbrig, Fruzaqla |
| Tempus Ai, INC | $184.44 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $172.33 | 2022-2025 | Tecentriq, Polivy, Alecensa |
| Asd Specialty Healthcare, LLC | $172.01 | 2019 | |
| Dendreon Pharmaceuticals LLC | $169.56 | 2021-2025 | Provenge |
| Rigel Pharmaceuticals, INC. | $162.07 | 2021-2023 | Rezlidhia, Tavalisse |
| Karyopharm Therapeutics INC. | $157.69 | 2021-2024 | Xpovio |
| Servier Pharmaceuticals LLC | $156.64 | 2023-2025 | |
| Tolmar Pharmaceuticals, INC. | $139.91 | 2022 | |
| Caris Mpi, INC. | $138.30 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $122.66 | 2024-2025 | |
| Beone Medicines USA, INC. | $108.34 | 2025 | Brukinsa, Tevimbra |
| Painteq LLC | $103.79 | 2023 | Painteq |
| Accord Healthcare, INC. | $99.87 | 2025 | |
| Amneal Pharmaceuticals LLC | $95.16 | 2025 | Alymsys |
| Taiho Oncology, INC. | $91.64 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $88.64 | 2024-2025 | Enjaymo, Sylvant |
| Novocure INC. | $75.46 | 2024-2025 | Optune, Optune Gio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.74 | 2022-2024 | |
| Stemline Therapeutics INC. | $67.76 | 2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $67.18 | 2024-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $66.66 | 2022-2024 | Fotivda |
| Octapharma USA, INC. | $64.76 | 2022-2023 | Octagam Immune Globulin (Human) |
| Sun Pharmaceutical Industries INC. | $64.10 | 2023-2024 | Yonsa, Odomzo |
| Pharmaessentia USA Corporation | $59.29 | 2022-2023 | Besremi |
| Teva Pharmaceuticals USA, INC. | $56.59 | 2019-2020 | |
| Gilead Sciences, INC. | $50.65 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $47.13 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $41.25 | 2019-2025 | Pyrukynd |
| Tolmar, INC. | $35.65 | 2023 | |
| Janssen Pharmaceuticals, INC | $32.17 | 2021 | |
| Tersera Therapeutics LLC | $28.88 | 2025 | Quzyttir |
| G1 Therapeutics, INC. | $28.35 | 2023 | Cosela |
| Iovance Biotherapeutics, INC. | $28.25 | 2025 | Amtagvi |
| Delcath Systems | $27.17 | 2025 | Hepzato Kit |
| Clovis Oncology, INC. | $26.69 | 2019 | |
| Csl Behring | $26.08 | 2021 | |
| Abbott Laboratories | $25.87 | 2021 | |
| Geron Corporation | $25.76 | 2025 | Rytelo |
| Exelixis INC. | $25.19 | 2019 | |
| Syndax Pharmaceuticals, INC. | $22.41 | 2025 | |
| Fennec Pharmaceuticals, INC. | $22.29 | 2025 | Fyarro |
| Shield Therapeutics INC | $20.14 | 2024 | |
| Array Biopharma INC | $19.61 | 2025 | Mektovi, Tukysa, Braftovi |
| Partner Therapeutics, INC. | $19.28 | 2019 | |
| Organon LLC | $18.42 | 2025 | |
| Pharmacosmos Therapeutics INC. | $17.85 | 2024 | Cosela |
| Adaptive Biotechnologies Corporation | $17.14 | 2025 | Clonoseq |
| Eusa Pharma (US) LLC | $16.81 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.52 | 2019 | |
| Morphosys, US INC. | $15.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.